Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.
MitraClip
Mitral regurgitation
Transcatheter edge‐to‐edge repair
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
07 Jun 2024
07 Jun 2024
Historique:
revised:
24
04
2024
received:
11
04
2024
accepted:
30
04
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
7
6
2024
Statut:
aheadofprint
Résumé
The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials. The RESHAPE-HF2 study is an investigator-initiated, prospective, randomized, multicentre trial including patients with symptomatic HF, a left ventricular ejection fraction (LVEF) between 20% and 50% with moderate-to-severe or severe FMR, for whom isolated mitral valve surgery was not recommended. Patients were randomized 1:1 to a strategy of delivering or withholding MitraClip. Of 506 patients randomized, the mean age of the patients was 70 ± 10 years, and 99 of them (20%) were women. The median EuroSCORE II was 5.3 (2.8-9.0) and median plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) was 2745 (1407-5385) pg/ml. Most patients were prescribed beta-blockers (96%), diuretics (96%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (82%) and mineralocorticoid receptor antagonists (82%). The use of sodium-glucose cotransporter 2 inhibitors was rare (7%). Cardiac resynchronization therapy (CRT) devices had been previously implanted in 29% of patients. Mean LVEF, left ventricular end-diastolic volume and effective regurgitant orifice area (EROA) were 31 ± 8%, 211 ± 76 ml and 0.25 ± 0.08 cm Patients enrolled in RESHAPE-HF2 represent a third distinct population where MitraClip was tested in, that is one mainly comprising of patients with moderate-to-severe FMR instead of only severe FMR, as enrolled in the COAPT and MITRA-FR trials. The results of RESHAPE-HF2 will provide crucial insights regarding broader application of the transcatheter edge-to-edge repair procedure in clinical practice.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Abbott Fund
Informations de copyright
© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez‐Sarano M. Burden of valvular heart diseases: A population‐based study. Lancet 2006;368:1005–1011. https://doi.org/10.1016/S0140‐6736(06)69208‐8
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics 2016 update: A report from the American Heart Association. Circulation 2016;133:e38–e360. https://doi.org/10.1161/CIR.0000000000000350
Levine RA, Schwammenthal E. Ischemic mitral regurgitation on the threshold of a solution: From paradoxes to unifying concepts. Circulation 2005;112:745–758. https://doi.org/10.1161/CIRCULATIONAHA.104.486720
Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non‐ischaemic dilated cardiomyopathy. Heart 2011;97:1675–1680. https://doi.org/10.1136/hrt.2011.225789
Vajapey R, Kwon D. Guide to functional mitral regurgitation: A contemporary review. Cardiovasc Diagn Ther 2021;11:781–792. https://doi.org/10.21037/cdt‐20‐277
Stone GW, Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, et al.; Mitral Valve Academic Research Consortium (MVARC). Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: Part 1: Clinical trial design principles: A consensus document from the Mitral Valve Academic Research Consortium. J Am Coll Cardiol 2015;66:278–307. https://doi.org/10.1016/j.jacc.2015.05.046
Barnes C, Sharma H, Gamble J, Dawkins S. Management of secondary mitral regurgitation: From drugs to devices. Heart. https://doi.org/10.1136/heartjnl‐2022‐322001. Published online ahead of print 22/08/23.
Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Fleisher LA, et al. 2017 AHA/ACC Focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252–289. https://doi.org/10.1016/j.jacc.2017.03.011
Baumgartner H, Falk V, Bax JJ, de Bonis M, Hamm C, Holm PJ, et al.; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739–2791. https://doi.org/10.1093/eurheartj/ehx391
Obadia JF, Messika‐Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al.; MITRA‐FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:2297–2306. https://doi.org/10.1056/NEJMoa1805374
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al.; COAPT Investigators. Transcatheter mitral‐valve repair in patients with heart failure. N Engl J Med 2018;379:2307–2318. https://doi.org/10.1056/NEJMoa1806640
Nappi F, Nenna A, Sing SSA, Timofeeva I, Mihos C, Gentile F, et al. Mitral regurgitation: Lessons learned from COAPT and MITRA‐Fr. J Thorac Dis 2020;12:2936–2944. https://doi.org/10.21037/jtd.2020.01.67
Grayburn PA, Chandrashekhar YS. Functional mitral regurgitation: More questions than answers. JACC Cardiovasc Imaging 2021;14:711–714. https://doi.org/10.1016/j.jcmg.2021.03.001
Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation: A new conceptual framework that reconciles the results of the MITRA‐FR and COAPT trials. JACC Cardiovasc Imaging 2019;12:353–362. https://doi.org/10.1016/j.jcmg.2018.11.006
Pibarot P, Delgado V, Bax JJ. MITRA‐FR vs. COAPT: Lessons from two trials with diametrically opposed results. Eur Heart J Cardiovasc Imaging 2019;20:620–624. https://doi.org/10.1093/ehjci/jez073
Anker SD, Friede T, von Bardeleben RS, Butler J, Fatima K, Diek M, et al. Randomised investigation of MitraClip device in heart failure: Design and rationale of the RESHAPE‐HF2 trial. Eur J Heart Fail. https://doi.org/10.1002/ejhf.3247 Published online ahead of print 23/04/24.
Levine RA, Hagége AA, Judge DP, Padala M, Dal‐Bianco JP, Aikawa E, et al.; Leducq Mitral Transatlantic Network. Mitral valve disease – morphology and mechanisms. Nat Rev Cardiol 2015;12:689–710. https://doi.org/10.1038/nrcardio.2015.161
Varma PK, Krishna N, Jose RL, Madkaiker AN. Ischemic mitral regurgitation. Ann Card Anaesth 2017;20:432–439. https://doi.org/10.4103/aca.ACA_58_17
Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes‐Genis A, Butler J, et al. Natriuretic peptides: Role in the diagnosis and management of heart failure: A scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Eur J Heart Fail 2023;25:616–631. https://doi.org/10.1002/ejhf.2848
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al.; Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731. https://doi.org/10.1002/ejhf.1494
Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 2019;139:1354–1365. https://doi.org/10.1161/CIRCULATIONAHA.118.037077
Rosano GMC, Farkas J. Evolving targets for heart failure: The journey so far. Global Cardiol 2023;1:3–6. https://doi.org/10.4081/cardio.2023.6
Siddiqi TJ, Butler J, Coats AJ, Verma S, Friede T, Filippatos G, et al. SGLT2 inhibitors and risk reduction for mortality in high‐risk patients: A meta‐analysis of randomized controlled trials. Global Cardiol 2023;1:55–60. https://doi.org/10.4081/cardio.2023.2
Capomolla S, Febo O, Gnemmi M, Riccardi G, Opasich C, Caporotondi A, et al. Beta‐blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000;139:596–608. https://doi.org/10.1016/s0002‐8703(00)90036‐x
Seneviratne B, Moore GA, West PD. Effect of captopril on functional mitral regurgitation in dilated heart failure: A randomised double blind placebo controlled trial. Br Heart J 1994;72:63–68. https://doi.org/10.1136/hrt.72.1.63
Rosano GMC. Clinical trial design, endpoints and regulatory considerations in heart failure. Global Cardiol. https://doi.org/10.4081/cardio.2024.18. Published online ahead of print 28/03/24.